Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 283.09 USD 0.8% Market Closed
Market Cap: 152.2B USD

During the last 3 months Amgen Inc insiders have not bought any shares, and sold 21.1m USD worth of shares. The stock price has increased by 1% over this period (open performance analysis).

The last transaction was made on Feb 21, 2025 by Reese David M , who sold 7.7m USD worth of AMGN shares.

Last Transactions:
Reese David M
$-7.7m
Miller Derek
$-447.7k
Santos Esteban
Executive Vice President and Chief Financial Officer (CFO)
$-2.6m
Gordon Murdo
Senior Vice President, Head of Regional General Management
$-2.6m
Graham Jonathan P
Executive Vice President, Global Commercial Operations
$-7.3m
Grygiel Nancy A.
Senior Vice President, Corporate Secretary and Chief Compliance Officer
$-483.8k
Grygiel Nancy A.
Senior Vice President, Corporate Secretary and Chief Compliance Officer
$-662.8k
Grygiel Nancy A.
Senior Vice President, Corporate Secretary and Chief Compliance Officer
$-572.3k
Graham Jonathan P
Executive Vice President, Global Commercial Operations
$-2.7m
Gordon Murdo
$-2.5m
Khosla Rachna
Senior Vice President, Strategy & Corporate Affairs
$-113.4k
Grygiel Nancy A.
Senior Vice President, Corporate Secretary and Chief Compliance Officer
$-160k
Williams R Sanders
Senior Vice President and General Counsel
$-50k
Eckert Robert
Board Member
$-1.6m
Williams R Sanders
Senior Vice President and General Counsel
$-150k
Graham Jonathan P
Executive Vice President, Global Commercial Operations
$-3.3m
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-250.6k
Grygiel Nancy A.
Senior Vice President, Corporate Secretary and Chief Compliance Officer
$-631.3k
Williams R Sanders
Senior Vice President and General Counsel
$-62.9k
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-250k
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-231.5k
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-238.4k
Williams R Sanders
Senior Vice President and General Counsel
$-59.5k
Graham Jonathan P
Executive Vice President, Global Commercial Operations
$-2.6m
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-236k
Williams R Sanders
Senior Vice President and General Counsel
$-60.6k
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-241k
Williams R Sanders
Senior Vice President and General Counsel
$-60.7k
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-259.8k
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-228.5k
Sugar Ronald D
Senior Vice President, Global Commercial Operations
$-229.3k
Williams R Sanders
Senior Vice President and General Counsel
$-100.9k
View All Transactions

During the last 3 months Amgen Inc insiders have not bought any shares, and sold 21.1m USD worth of shares. The stock price has increased by 1% over this period (open performance analysis).

The last transaction was made on Feb 21, 2025 by Reese David M , who sold 7.7m USD worth of AMGN shares.

Sold
0-3
months
21.1m USD
6
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
662.8k USD
1
Bought
0-3
months
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
0
0 USD

Amgen Inc
Insider Trading Chart

Amgen Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Amgen Inc
Last Insider Transactions

Global
Insiders Monitor

Amgen Inc
Glance View

Economic Moat
Wide
Market Cap
152B USD
Industry
Biotechnology

Amgen Inc., a towering figure in the biopharmaceutical industry, started its journey in the early 1980s in Thousand Oaks, California, with a visionary commitment to tapping into the potential of recombinant DNA technology. This leap into biotechnology allowed the company to produce vital proteins that the body naturally lacks in certain medical conditions. Concentrating on serious illnesses such as cancer, kidney failure, and rheumatoid arthritis, Amgen transformed itself over the decades from a novel research lab into a global powerhouse, rolling out revolutionary therapies like Epogen and Neulasta. These blockbuster drugs, designed to treat anemia and prevent infections in chemotherapy patients, catapulted Amgen into the echelon of companies that not only evolve with science but also shape its trajectory. Today, Amgen thrives by blending its innovative science with strategic acquisitions, expanding its pipeline beyond merely biological drugs to include biosimilars and small molecule medicines. The company's revenue stream relies heavily on its existing successful therapies while also banking on the future with investments in genetic research and novel drug developments. By leveraging their expertise in biotechnology and clinical trials, Amgen is able to bring new products to market and navigate the complex regulatory landscape efficiently. The firm expertly balances risk and reward, ensuring a steady influx of cash flow through both established product lines and the advent of new therapies. Thus, Amgen, with its robust portfolio and strategic business maneuvers, continues to play a pivotal role in enhancing patient outcomes while reinforcing its position as a leader in the biopharmaceutical realm.

AMGN Intrinsic Value
255.17 USD
Overvaluation 10%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top